Schizophrenia Schizoaffective Disorder clinical trials

Explore recruiting schizophrenia schizoaffective disorder clinical trials.

Recruiting schizophrenia schizoaffective disorder studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Schizophrenia Schizoaffective Disorder trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for schizophrenia compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.

Austria, Germany, Spain, Italy

Therapeutic use (Phase IV) EU CTIS Study details

Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study.

Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)

Croatia

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major depressive disorder and bipolar depression compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.

Germany, Italy, Austria, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Schizophrenia Schizoaffective Disorder trials by city

Schizophrenia Schizoaffective Disorder in Toronto Schizophrenia Schizoaffective Disorder in Vancouver Schizophrenia Schizoaffective Disorder in Montreal Schizophrenia Schizoaffective Disorder in Calgary Schizophrenia Schizoaffective Disorder in Edmonton Schizophrenia Schizoaffective Disorder in Ottawa Schizophrenia Schizoaffective Disorder in Winnipeg Schizophrenia Schizoaffective Disorder in Quebec City Schizophrenia Schizoaffective Disorder in Hamilton Schizophrenia Schizoaffective Disorder in Kitchener Schizophrenia Schizoaffective Disorder in London Schizophrenia Schizoaffective Disorder in Halifax Schizophrenia Schizoaffective Disorder in New York Schizophrenia Schizoaffective Disorder in Los Angeles Schizophrenia Schizoaffective Disorder in Chicago Schizophrenia Schizoaffective Disorder in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease